Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with or without ISA101b in HPV16-positive oropharyngeal cancer
NL-OMON52570Phase 2Completed
- Sponsor
- ISA Pharmaceuticals
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cemiplimab and SLP-HPV-01 in oropharyngeal cancer and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by ISA Pharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
oropharyngeal cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON52570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52570.